Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31519530 | 0.91 | ALDH1A1 (0.46) | ALDH1A1TSHRALOX5HTR3ESLC22A2 | |
| SCHEMBL838588 | 0.91 | ALDH1A1 (0.46) | ALDH1A1TSHRALOX5HTR3ESLC22A2 | |
| SCHEMBL10827293 | 0.84 | TSHR (0.46) | ALDH1A1TSHRHTR3ESLC22A2SLC22A1 | |
| SCHEMBL28431559 | 0.80 | TSHR (0.50) | ALDH1A1TSHRALOX5PNMTTAAR1 | |
| Nitrogen SCHEMBL1855525 | 0.73 | TSHR (0.44) | ALDH1A1TSHRALOX5PNMTTAAR1 | |
| SCHEMBL5421594 | 0.73 | CYP1A2 (0.48) | ALDH1A1TSHRMAPTMEN1KMT2A | |
| SCHEMBL4949117 | 0.73 | ACHE (0.48) | ALDH1A1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2890615 | 0.73 | KDM1A (0.39) | ALDH1A1TSHRTAAR1HTR2AHTR2C | |
| SCHEMBL92061 | 0.72 | LMNA (0.40) | TSHRHTR2AHTR2CHTR2BMEN1 | |
| SCHEMBL29085609 | 0.71 | MEN1 (0.48) | ALDH1A1TSHRALOX5PNMTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| EP-2027090-A2 | MGLUR5 MODULATORS II | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| EP-2027110-A2 | MGLUR5 MODULATORS III | Astra Zeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| EP-2027120-A2 | MGLUR5 MODULATORS I | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1919911-A1 | BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130822-A2 | MGLUR5 MODULATORS III | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007021574-A1 | BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | GRM5, GRM1, GRIN1 | ALDH1A1 769/4885TSHR 998/4885ALOX5 1272/4885 |
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | ALDH1A1 4350/4885TSHR 1225/4885ALOX5 641/4885 |
| US-20070259926-A1 | mGluR5 modulators III | GRM5, GRM3, GRIK5 | ALDH1A1 4536/4885TSHR 1201/4885ALOX5 646/4885 |
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | ALDH1A1 4552/4885TSHR 1270/4885ALOX5 645/4885 |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | ALDH1A1 3756/4885TSHR 607/4885ALOX5 3030/4885 |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | GRM5, GRM1, GRIN1 | ALDH1A1 769/4885TSHR 998/4885ALOX5 1272/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | ALDH1A1 3616/4885TSHR 618/4885ALOX5 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.